Intranasal Antibody Shows Promise in Protecting Against Flu
A novel approach to preventing influenza, involving the twice-daily application of a broadly neutralizing antibody via the nose, is showing promising results. Research conducted by a Dutch group has demonstrated effectiveness in both mice and macaques, with initial safety data established in a human clinical trial. The findings were published in Science Translational Medicine in March 2026.
The Challenge of Flu Prevention
Influenza viruses are notorious for their ability to mutate, making it hard to develop long-lasting immunity through traditional vaccination methods. Researchers have been exploring alternative strategies, including the use of broadly neutralizing antibodies (bnAbs) – antibodies that can recognize and neutralize a wide range of influenza A and B viruses.
Johnson & Johnson’s Early Research
As early as 2012, scientists at Johnson & Johnson discovered antibodies with broad neutralizing activity against influenza viruses. However, initial attempts to protect mice from infection through intravenous administration of these antibodies proved unreliable. This led to a pause in clinical development of this approach.
Reviving the Intranasal Approach
The Dutch research group revisited the concept of using bnAbs for influenza prevention, focusing on intranasal administration. This method aims to deliver the antibody directly to the site of infection – the nasal passages – providing localized protection. Studies in mice and macaques showed that twice-daily intranasal application of the bnAb effectively prevented influenza infection.
Human Clinical Trial Results
A clinical trial involving humans assessed the safety of the intranasal antibody administration. The results indicated that the approach was well-tolerated, paving the way for further research to evaluate its efficacy in preventing influenza in humans.
Johnson & Johnson’s Presence in Leiden
Johnson & Johnson has a significant presence in Leiden, Netherlands, with its subsidiary Janssen Biologics actively expanding its facilities at the Leiden Bio Science Park. The company has a long-standing relationship with Sisk, having collaborated on projects in the region for over a decade, including expansions to accommodate vaccine production, particularly in response to the COVID-19 pandemic. Recent investments, such as the Optima building, are designed to support the growth and innovation of their manufacturing capabilities. J&J Innovative Medicine is dedicated to advancing medical breakthroughs.
Future Directions
Whereas the initial results are encouraging, further research is needed to determine the optimal dosage, duration of protection, and long-term effects of intranasal bnAb administration. Larger clinical trials will be crucial to confirm the efficacy of this approach in preventing influenza in diverse populations. If successful, this could represent a significant advancement in influenza prevention strategies, offering a new layer of protection against this common and potentially serious respiratory illness.